AstraZeneca provides update on phase III trial of selumetinib in non-small cell lung cancer
Selumetinib did not meet trial endpoint of progression-free survival in KRASm NSCLC patients.
Selumetinib did not meet trial endpoint of progression-free survival in KRASm NSCLC patients.
AstraZeneca today announced that the Phase III SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival.
AstraZeneca meddelar idag att den första patienten har randomiserats till det kliniska fas 3 programmet för selumetinib, en oral, potent, selektiv MEK-hämmare, vilken utvecklas som andra linjens behandling för patienter med avancerad eller metastaserad icke-småcellig lungcancer (non-small-cell lung cancer, NSCLC) med tumörer som har KRAS mutationer.